InMed Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's

 

• INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer's

• Statistically significant reduction in neurodegeneration marker, neurofilament light chain ('NfL')

• mRNA profile showed a reduction of several key neuroinflammatory genes in the brain

 InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces positive results from a long-term in vivo preclinical Alzheimer's Disease ('AD') study. In the study, INM-901 demonstrated a reduction in several plasma and brain markers of neuroinflammation, a recognized contributor to Alzheimer's disease development and progression.

https://www.newsfilecorp.com/release/237884/InMeds-INM901-Demonstrates-Statistically-Significant-Reduction-in-Neuroinflammation-in-a-LongTerm-Preclinical-Alzheimers-Disease-Study